Mettler-Toledo Intl (MTD) Fundamental Analysis: Bull vs. Bear Case

MTD

Mettler-Toledo Intl

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Diagnostics & Research

Exchange

NYSE

County of HQ

United States

Next Earnings Date

05/07/26

Business Summary

The company generates cash by selling precision instruments, laboratory equipment, and measurement technologies that are embedded into research and industrial workflows. Its moat comes from high switching costs, calibration ecosystems, and integration into regulated processes where accuracy and compliance are non-negotiable. Once installed, systems require ongoing servicing, validation, and replacement cycles, creating durable revenue streams. The combination of precision engineering, brand credibility, and workflow entrenchment forms a defensible competitive position that supports sustained high returns on invested capital.

VALUATION

P/E

31.6 Market Cap ($M USD)

$26,829

Forward P/E

25.9 PEG

4.2 PRICE TO SALES

6.8 PRICE TO BOOK

-

EV / EBITDA

23.3 5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0 5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$42.17

Next Year EPS Growth Estimate

$51.19

Next Year Revenue Growth Estimate

4.90%

Return on Equity (ROE)

-3677.40%

FREE CASH FLOW

Operating Margin

27.80%

Debt-to-Equity

-

Piotroski F-Score

6 Altman Z-Score

9.9 Return on Invested Capital (ROIC)

44.10%

Current Ratio

1.1 Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Gainseekers Quantitative Analysis

Summary

At 31.6x earnings and 25.9x forward earnings, the stock is not statistically cheap, but it is trading at a multiple that implies durable growth rather than speculative excess. The 4.2 forward PEG suggests investors are paying a premium relative to near-term growth expectations, yet the 9.9 Altman Z-Score signals extremely low bankruptcy risk and strong balance sheet stability. With a $26,829M market cap and ROIC of 44.10%, this is a high-quality compounder priced for execution perfection rather than distress. The market is not mispricing insolvency risk; it is pricing durability and capital efficiency, and the valuation leaves little margin for operational disappointment.

AI Exposure / Tech Reliance

As a Diagnostics & Research company within Healthcare, it sits in a data-intensive, precision-driven vertical that increasingly integrates automation and AI-enhanced analytics. The ability to embed advanced software, measurement systems, and data workflows into laboratory environments makes the business inherently aligned with digital transformation trends. Industry digitization supports recurring equipment demand and embedded technological relevance.

The Bull Case

A GARP investor buys this because 44.10% ROIC is elite capital efficiency, indicating a business that converts invested capital into substantial returns. The Piotroski F-Score of 6 reflects solid, if not perfect, financial health, while the 9.9 Altman Z-Score reinforces structural safety. Despite the optically extreme -3677.40% operating margin figure, the company still produces 4.90% return on equity and maintains a manageable 27.80% debt-to-equity ratio alongside a 1.1 current ratio, suggesting liquidity adequacy. The forward P/E of 25.9 relative to current P/E of 31.6 implies earnings expansion, and with EPS at 23.3 and next year’s estimated EPS of $42.17, the earnings inflection narrative is the core institutional tailwind.

The Bear Case

The 4.2 forward PEG ratio is the first red flag—investors are paying a steep premium relative to expected growth, which compresses future upside. A 27.80% debt-to-equity ratio is not alarming, but in combination with a thin 1.1 current ratio, it leaves limited room for cyclical shocks. The -3677.40% operating margin figure is deeply concerning on its face and demands scrutiny, as it signals severe reported operating pressure. With no dividend, no yield, and a consensus rating figure of 2.90% alongside a mean consensus target price of 2, sentiment indicators appear distorted or weak, reinforcing that this is a valuation-sensitive name where multiple compression is the primary risk.

Market Sentiment & Smart Money

Short Interest %

2.90%

Analyst Consensus

2 Average Analyst Price Target

$1,510.61

Institutional Ownership %

103.00%

1-Year Beta

1.35 Insider Buying % (6 Mo)

0.40%%

Distance to 52-Week High

86.90%

Distance to 52-Week Low

137.70%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.